FAA Proposes Easing Medical Rules for Non-Insulin Diabetes
The FAA has proposed a rule change allowing pilots with diabetes controlled by non-insulin medications to receive medical certificates directly from
The Federal Aviation Administration proposed a rule change on Thursday that would ease medical certification for pilots with diabetes. The new rule would allow pilots whose condition is managed with non-insulin medications to potentially receive first-, second-, or third-class medical certificates without undergoing the agency's Special Issuance process.
Under current regulations, diabetes requiring any hypoglycemic drug is a specifically disqualifying condition. While pilots using non-insulin treatments can still qualify, their applications are generally deferred by aviation medical examiners to the FAA for a Special Issuance review. The proposal would remove non-insulin medications from that provision, allowing qualified applicants to be evaluated under the FAA's general medical standards instead.
Rationale for the Change
The FAA stated that advances in treatment justify the update. "The availability of numerous new diabetes medication classes and other non-insulin treatments has substantially improved disease management," the agency said in the proposed rule. It noted that the existing diabetes standard dates to 1959 and that modern treatments have reduced severe complications like cardiovascular events and hypoglycemia.
The agency estimates the change would allow aviation medical examiners to issue certificates at the time of examination in roughly 3,000 cases annually. An additional 1,200 cases currently handled through Special Issuance could transition to AME-managed certification. Over five years, the FAA projects the change would save applicants between $39.7 million and $80.2 million in labor costs.
"Processing all NIDDM cases via the SI process places a burden on applicants and FAA," the agency stated. It expects the proposal to reduce certification wait times, lower the FAA's processing workload, and shorten the process for pilots with well-controlled diabetes.
Safety Review and Limitations
As part of its proposal, the FAA conducted a safety review of fatal accidents involving pilots using non-insulin diabetes medications. The agency examined 51 fatal accidents from 2008 through 2025. It determined that diabetes, related complications, or diabetes medication were unlikely to have contributed to 50 of those accidents. One case remains under investigation.
The proposed change has clear limits. It would not alter requirements for pilots whose diabetes is treated with insulin; they would still require Special Issuance authorization. Also, pilots using non-insulin treatments could still be denied or have their applications deferred on a case-by-case basis. This would occur if the FAA or an aviation medical examiner determines the condition or treatment could interfere with the safe exercise of pilot privileges.
The proposed rule is scheduled for publication in the Federal Register on Friday. The FAA will accept public comments on the proposal for 30 days following its publication.
